Abstract Secondary osteoporosis is a common side effect of glucocorticoid treatments. The anti-osteoporotic role of two fermented milk products (FMPs), produced with Lactobacillus plantarum A41 and Lactobacillus fermentum SRK414, in alleviating secondary osteoporotic symptoms induced by dexamethasone (Dex) injection in rats was investigated. The two FMPs could prevent Dex-induced bone loss in rats. The two FMPs normalised altered gene expression levels of bone metabolism-related markers (osteoprotegerin, osteocalcin, bone sialoprotein, receptor activator of nuclear factor kappa-B ligand, and tartrate-resistant acid phosphatase). Furthermore, they regulated gene expression levels of bone morphogenetic protein 2-related and cell apoptosis markers in the tibia and calcium metabolism-related markers in the ileum. Additionally, these treatments modulated faecal bacterial populations by increasing Lactobacillus colonies. FMPs fermented by L. plantarum A41 and L. fermentum SRK414 were capable of preventing glucocorticoid-induced secondary osteoporosis via regulation of intestinal microbiota and gene expression levels of bone cell apoptosis related markers.

中文翻译：

---

在糖皮质激素诱导的继发性骨质疏松症大鼠模型中使用乳酸菌发酵乳制品预防骨质流失

摘要继发性骨质疏松症是糖皮质激素治疗的常见副作用。研究了用植物乳杆菌 A41 和发酵乳杆菌 SRK414 生产的两种发酵乳制品 (FMP) 在减轻由地塞米松 (Dex) 注射引起的大鼠继发性骨质疏松症状中的抗骨质疏松作用。这两种 FMP 可以防止 Dex 诱导的大鼠骨质流失。这两种 FMP 使骨代谢相关标志物（骨保护素、骨钙素、骨唾液蛋白、核因子 kappa-B 配体的受体激活剂和抗酒石酸酸性磷酸酶）的基因表达水平正常化。此外，它们调节胫骨中骨形态发生蛋白 2 相关和细胞凋亡标志物以及回肠中钙代谢相关标志物的基因表达水平。此外，这些处理通过增加乳杆菌菌落来调节粪便细菌种群。植物乳杆菌 A41 和发酵乳杆菌 SRK414 发酵的 FMP 能够通过调节肠道微生物群和骨细胞凋亡相关标志物的基因表达水平来预防糖皮质激素诱导的继发性骨质疏松症。